Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pleconaril SCHEMBL4656259 | 1.00 | NR1I2 (1.00) | NR1I2CYP3A4CYP2D6HDAC6HDAC1 | |
| SCHEMBL8135235 | 0.96 | NR1I2 (0.92) | NR1I2CYP3A4CYP2D6HDAC6HDAC1 | |
| SCHEMBL8874837 | 0.96 | NR1I2 (0.92) | NR1I2CYP3A4CYP2D6HDAC6HDAC1 | |
| SCHEMBL8876306 | 0.94 | NR1I2 (0.88) | NR1I2CYP3A4CYP2D6HDAC6HDAC1 | |
| SCHEMBL8874464 | 0.93 | NR1I2 (0.86) | NR1I2CYP3A4CYP2D6HDAC6HDAC1 | |
| SCHEMBL8874452 | 0.92 | NR1I2 (0.86) | NR1I2CYP3A4CYP2D6HDAC6HDAC1 | |
| SCHEMBL8877950 | 0.92 | NR1I2 (0.86) | NR1I2CYP3A4CYP2D6HDAC6HDAC1 | |
| SCHEMBL8875252 | 0.91 | NR1I2 (0.84) | NR1I2CYP3A4CYP2D6HDAC6HDAC1 | |
| SCHEMBL8875401 | 0.91 | NR1I2 (0.84) | NR1I2CYP3A4CYP2D6HDAC6HDAC1 | |
| SCHEMBL13623352 | 0.91 | NR1I2 (0.83) | NR1I2CYP3A4CYP2D6HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8113 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| US-12595280-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2026-04-07 | — | — | US | claimed |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | Tets, Viktor Veniaminovich (US) | 2026-04-02 | — | — | US | claimed |
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-3534910-B1 | RIFAMPICIN DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | POP TEST ONCOLOGY LLC (US) | 2026-03-25 | — | — | EP | claimed |
| WO-2002009699-A2 | METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT | IMMUPHARM APS (DK) | 2002-02-07 | — | — | WO | claimed |
| WO-2001038313-A1 | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038314-A1 | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038312-A1 | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001037837-A1 | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001019822-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2001-03-22 | — | — | WO | claimed |
| WO-2001019322-A2 | USE OF CSAIDS IN RHINOVIRUS INFECTION | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-22 | — | — | WO | claimed |
| EP-0566199-B1 | 1,2,4-Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | SANOFI SA (FR) | 2000-03-01 | — | — | EP | claimed |
| US-5464848-A | 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | STERLING WINTHROP INC. (US) | 1995-11-07 | — | — | US | claimed |
| EP-0566199-A1 | 1,2,4-Oxadiazolyl-phenoxyalkylisoxazoles and their use a s antiviral agents | STERLING WINTHROP INC. (US) | 1993-10-20 | — | — | EP | claimed |